Stocks · News reference

HC Wainwright & Co. Reiterates Buy on Actuate Therapeutics, Maintains $15 Price Target

Aug 18, 2026, 10:38 AMBenzinga Newsdesk

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Actuate Therapeutics (NASDAQ:ACTU) with a Buy and maintains $15 price target.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source: benzinga
Observed: Aug 18, 2026, 10:38 AM
Checked: Aug 18, 2026, 10:38 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaSep 9, 2026, 11:10 AMBenzinga Newsdesk
Actuate Therapeutics Says Preclinical Studies Showed Synergistic Activity Of Elraglusib Combined With Revolution Medicines' Zoldonrasib And Daraxonrasib In Pancreatic Cancer Models
ACTU
BenzingaJul 30, 2026, 3:41 PMAvi Kapoor
This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
ACTU BE KYMR SFM SKHY
BenzingaJul 30, 2026, 12:21 PMBenzinga Newsdesk
Rodman & Renshaw Initiates Coverage On Actuate Therapeutics with Buy Rating, Announces Price Target of $6
ACTU